CATALYSTYahoo Finance • 10h ago
DataMeds Regains Compliance With NASDAQ Listing StandardsYahoo Finance report covering DataMeds AI Inc. (MEDS) market action, institutional positioning, and fundamental catalysts.
Why MEDS Stock dropped -5.42% Today — RQD Quant Desk Flash
$1.92 -5.42% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.90
DataMeds AI Inc. (MEDS) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $9.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on MEDS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is MEDS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, DataMeds AI Inc. (NASDAQ: MEDS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.92 (-5.42% 1D, market cap $9.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MEDS ranks #911 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does MEDS compare to HKPD and COSM in the Health Care sector?
▼
Within the Health Care sector (Other Pharmaceuticals), MEDS carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of -27.5%, and ROIC of -35.0%. By comparison, HKPD (Cellyan Biotechnology Co. Ltd (Class A)) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $5.4M) and COSM (Cosmos Health Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $27.9M). Among the 5-stock peer group, MEDS leads on earnings multiple (N/A) while MEDS leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for MEDS?
▼
Per MEDS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002030763), DataMeds AI Inc. generated $23.3M in revenue (+28.7% YoY), -$101.3M in net income, and -$10.9M in free cash flow against $30.5M in total assets and $12.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.90 (-1.17%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-13.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MEDS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
🔍 WHY MEDS SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (25% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$3.07-13% Next Q
36
Q2 (-2Q)Grade E$2.67-18% Next Q
33
Q3 (-1Q)Grade E$2.19-12.3% Next Q
31
CurrentGrade E$1.92-10% Hist 90D α
28
Trajectory: E (36) → E (28)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a MEDS Turnaround Squeeze
While MEDS currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.48) and Max Pain ($2.02) forces dealer call-delta covering toward $40.43.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $MEDS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MEDS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MEDS Stock dropped -5.42% Today — RQD Quant Desk Flash
DataMeds AI Inc. (MEDS) dropped -5.42% to $1.92, trading at 3% of its 52-week range ($0.82 – $38.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 3% of its 52-week range ($0.82 – $38.5) with RSI-14 at 41.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.92 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 0% gross margin and $0 annual free cash flow.
Live MEDS Headlines & Catalysts
MARKET WIREStock Titan • 13h ago
A consumer weight-management license could require extra shares from DataMeds AI (Nasdaq: MEDS).Stock Titan report covering DataMeds AI Inc. (MEDS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 16h ago
DataMeds AI Stock Rises After Humana Adds Medicaid Coverage for ChemoFx Cancer TestBenzinga report covering DataMeds AI Inc. (MEDS) market action, institutional positioning, and fundamental catalysts.
CATALYSTkalkine.ca • 19h ago
Is DataMeds AI (NASDAQ:MEDS) Selling Into Strength After a 7.43% Gain and a Share Offering?kalkine.ca report covering DataMeds AI Inc. (MEDS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 22h ago
DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management PlatformYahoo Finance report covering DataMeds AI Inc. (MEDS) market action, institutional positioning, and fundamental catalysts.
CATALYSTTimothy Sykes • 1d ago
DataMeds AI Stock Surges As Revenue And Oncology Bets IgniteTimothy Sykes report covering DataMeds AI Inc. (MEDS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREKalkine • 1d ago
What Explains the 5.29% Premarket Decline for DataMEDS AI (NASDAQ:MEDS) on Oct 9?Kalkine report covering DataMeds AI Inc. (MEDS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A proposed health platform would combine patient-controlled data, biometric medication checks and automated delivery.Stock Titan report covering DataMeds AI Inc. (MEDS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 15h ago
DataMEDS AI Secures Supply Agreement for Six Compounded Peptides Following FDA Advisory Committee RecommendationsDataMEDS AI, Inc. (NASDAQ:MEDS) has announced that its pharmacy subsidiary, Corexa Health, has entered into a commercial supply agreement covering bulk drug substances and active pharmaceutical ingredients (APIs) for six
MARKET WIREBenzinga • 19h ago
DataMeds AI's Pharmacy Unit Corexa Health Enters Agreement For Commercial Supply Of Six Peptides Recommended By The FDA Pharmacy Compounding Advisory Committee; Intends To Start Distributing Prescriptions In November 2026DataMEDS intends to leverage the Health Lives Here mobile application to help collect and report safety data, in accordance with U.S. Health and Human Services' (HHS) Enforcement Discretion Policy (EDP) published in
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MEDS)
- ✓Walkthrough of MEDS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
MEDS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -63.08%📐 HORIZONTAL RANGE
2026-11-02O $2.20H $2.20L $1.92C $1.92VOL 227.9K
RES: $12.62SUP: $-0.73SMA50: $2.48SMA200: $5.77
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MEDS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +28.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on MEDS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MEDS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MEDS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MEDS)
Health Care Rank #911 of 1016
⚔️ HKPD vs MEDS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (MEDS vs. HKPD, COSM, ESYN, ZSTK)
Industry: Other Pharmaceuticals (10 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, DataMeds AI Inc. (MEDS) ranks #911 by composite RQD confidence (28/100, grade E) and #897 by equity capitalization ($9.8M). Within this direct 5-issuer industry benchmark cohort, MEDS leads on earnings valuation at N/A trailing P/E, while MEDS leads on capital efficiency and profitability with -35.0% ROIC and -27.5% gross margin. HKPD currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with MEDS at 28/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MEDS
ACTIVE
DataMeds AI Inc. | E | 28/100 | — | -27.5% | -35.0% | -5.42% | $9.8M | Benchmark Subject |
| HKPD Cellyan Biotechnology Co. Ltd (Class A) | D | 46/100 | — | — | — | -9.59% | $5.4M | /hkpd-vs-meds → |
| COSM Cosmos Health Inc. | E | 29/100 | — | 12.1% | -35.0% | +10.96% | $27.9M | /cosm-vs-meds → |
| ESYN EnerSyn Global Inc. | D- | 40/100 | — | 53.0% | -35.0% | -4.37% | $54.4M | /esyn-vs-meds → |
| ZSTK ZeroStack Corp. | E | 25/100 | — | 4.6% | -35.0% | -5.12% | $63.9M | /zstk-vs-meds → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002030763In its most recent audited fiscal period (FY2025, filed 2025-12-31), DataMeds AI Inc. (MEDS) reported GAAP revenue of $23.3M (+28.7% vs. FY2024 revenue of $18.1M ) , GAAP net income of -$101.3M, operating cash flow of -$10.9M, and free cash flow of -$10.9M (-786.1% YoY). On the balance sheet, MEDS closed FY2025 with $30.5M in total assets against $12.6M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $23.3M | -$101.3M | -$10.9M | -$10.9M | $30.5M | $12.6M |
| FY2024 (FY) | 2024-12-31 | $18.1M | -$6.9M | -$1.2M | -$1.2M | $57.3M | $11.5M |
| FY2023 (FY) | 2023-12-31 | $0 | -$2.9M | -$349.1K | -$349.1K | — | — |
3. MEDS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MEDS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, DataMeds AI Inc. (NASDAQ: MEDS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.92 (-5.42% 1D, market cap $9.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MEDS ranks #911 in composite RQD confidence.
How does MEDS compare to HKPD and COSM in the Health Care sector?
Within the Health Care sector (Other Pharmaceuticals), MEDS carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of -27.5%, and ROIC of -35.0%. By comparison, HKPD (Cellyan Biotechnology Co. Ltd (Class A)) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $5.4M) and COSM (Cosmos Health Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $27.9M). Among the 5-stock peer group, MEDS leads on earnings multiple (N/A) while MEDS leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MEDS?
Per MEDS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002030763), DataMeds AI Inc. generated $23.3M in revenue (+28.7% YoY), -$101.3M in net income, and -$10.9M in free cash flow against $30.5M in total assets and $12.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MEDS trading relative to its 50-day, 200-day, and 52-week technical levels?
MEDS last traded at $1.92 (-5.42% on volume of 146,476 shares), positioning the stock -22.58% below its 50-day simple moving average ($2.48) and -66.72% below its 200-day simple moving average ($5.77). Across its 52-week range of $0.82 to $38.50, MEDS sits at the 2.9% percentile with a 14-day RSI of 41.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.68 to $2.16).
MEDS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is MEDS stock moving today?
Why MEDS Stock dropped -5.42% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 28/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
MEDS — DataMeds AI Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:51:49Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, MEDS scores 28 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars break down as follows:
- Fundamental Cash Engine: 7 / 20 (ROIC -35%; FCF yield 0%). The cash-generation pillar is weak; the company is not converting operations into free cash flow or returns on invested capital.
- Whale 13F Flow: 3 / 20 (institutional accumulation and options positioning). The institutional-flow pillar is near the bottom of its range, indicating little supportive smart-money positioning per the rating inputs.
- Insider Conviction: 3 / 20 (SEC Form 4 and Congressional PTR cluster flow). Insider-conviction signals are weak per the rating.
- Macro Regime Fit: 7 / 20 (Beta 1.0; sector sensitivity). Beta of 1.0 places the stock at market-level sensitivity, but the rating assigns limited regime-fit credit.
- Forensic Balance Sheet: 8 / 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). The forensic pillar flags balance-sheet and accounting-quality concerns, with a low Piotroski F-Score.
For a prospective investor, the rating implies that upside depends on a turnaround in cash generation and sentiment, while the forensic and flow pillars currently point the other way. Valuation is difficult to anchor: forward earnings multiples are not available in the source data, and the reported losses mean conventional earnings-based comparisons cannot be drawn. The 52-week range of $0.82 to $38.5 and the current price of $2.03 show extreme price dispersion, which the rating reflects as high risk rather than as a signal in itself.
Business
DataMeds AI Inc. (MEDS) is a NASDAQ-listed issuer in the Health Care sector and Other Pharmaceuticals industry, per the profile. Per the recent news wire, the company has licensed U.S. rights to a direct-to-consumer GLP-1 weight-management platform and offers a ChemoFx cancer test that has been added to Medicaid coverage by Humana. Revenue is reported in the SEC financials, but the source data does not break revenue down by product or customer segment beyond these items. Not available in source data for detailed monetization mix.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $23.3M | $-93.7M | $-101.3M | N/A | $-10.9M | $0.0M | $12.6M |
| FY 2024 | $18.1M | $-6.1M | $-6.9M | N/A | $-1.2M | $1.0M | $11.5M |
| FY 2023 | $0.0M | $-2.9M | $-2.9M | N/A | $-0.3M | N/A | N/A |
Per the SEC financials, gross margin is -27.5%, operating margin is -60%, and net margin is -60%, with ROIC at -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, per the Roarable forensic inputs. Debt-to-equity is 0.5 and cash is reported as $0.0M for FY 2025, so the balance-sheet posture rests on minimal liquidity against $12.6M of reported debt.
Recent Catalysts & News Wire Analysis
- Regained NASDAQ compliance (CATALYST, GREEN): a headline reports DataMeds regaining compliance with NASDAQ listing standards.
- Possible extra share issuance (MARKET WIRE, YELLOW): a headline indicates a consumer weight-management license could require additional shares.
- Humana Medicaid coverage for ChemoFx (MARKET WIRE, YELLOW): a headline reports the stock rising after Humana added Medicaid coverage for the cancer test.
- Share offering and selling into strength (CATALYST, GREEN): a kalkine.ca headline questions selling after a 7.43% gain and a share offering.
- GLP-1 U.S. rights licensing (MARKET WIRE, YELLOW): a headline reports licensing of U.S. rights to a direct-to-consumer GLP-1 platform.
- Revenue and oncology bets (CATALYST, GREEN): a Timothy Sykes headline attributes a surge to revenue and oncology.
Risk watch items include the possible share dilution flagged in the license-related headline and the share offering referenced by kalkine.ca. The Butterfly Supply-Chain Graph reports no supply chain and no proprietary signals.
Open Questions
- What is the terms and share count of the consumer weight-management license that could require additional shares, and how large is the potential dilution?
- What were the size and terms of the recent share offering, and how much cash did it raise relative to the reported $0.0M cash position?
- What drove the revenue increase from $18.1M to $23.3M, and how much of it is recurring versus one-time?
- What explains the jump in net loss from $-6.9M to $-101.3M in FY 2025, and are there non-recurring charges?
- What are the terms of the debt reported at $12.6M, including maturities and covenants?
MEDS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for DataMeds AI Inc. (MEDS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 10h ago
DataMeds Regains Compliance With NASDAQ Listing Standards Yahoo Finance report covering DataMeds AI Inc. (MEDS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 13h ago
A consumer weight-management license could require extra shares from DataMeds AI (Nasdaq: MEDS). Stock Titan report covering DataMeds AI Inc. (MEDS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 16h ago
DataMeds AI Stock Rises After Humana Adds Medicaid Coverage for ChemoFx Cancer Test Benzinga report covering DataMeds AI Inc. (MEDS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST kalkine.ca • 19h ago
Is DataMeds AI (NASDAQ:MEDS) Selling Into Strength After a 7.43% Gain and a Share Offering? kalkine.ca report covering DataMeds AI Inc. (MEDS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 22h ago
DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform Yahoo Finance report covering DataMeds AI Inc. (MEDS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Timothy Sykes • 1d ago
DataMeds AI Stock Surges As Revenue And Oncology Bets Ignite Timothy Sykes report covering DataMeds AI Inc. (MEDS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Kalkine • 1d ago
What Explains the 5.29% Premarket Decline for DataMEDS AI (NASDAQ:MEDS) on Oct 9? Kalkine report covering DataMeds AI Inc. (MEDS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A proposed health platform would combine patient-controlled data, biometric medication checks and automated delivery. Stock Titan report covering DataMeds AI Inc. (MEDS) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
MEDS Bull vs. Bear Conversation Board — What's Your Call at $1.92?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MEDS 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $1.79 (-11.8%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is MEDS (E • RQD 28/100) a Buy at $2.03?
Welcome to the MEDS (DataMeds AI Inc.) Roar Pit. Current RQD Composite is 28/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Other Pharmaceuticals. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $1.58 (-22.2%)
Spot @ $2.03 Pump the brakes on MEDS — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on MEDS, but look at what you are paying: current EV/EBITDA multiples with -27.5% gross margins. Unless DataMeds AI Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH
🎯 Target: $2.44 (+20.2%)
Spot @ $2.03 MEDS cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on MEDS, the market is fixating on short-term headline noise in Other Pharmaceuticals and ignoring the balance sheet and cash flow trajectory. At $2.03 (52-wk range $0.82 - $38.50), any beat on forward guidance forces shorts and underweight funds to chase.